Just as a positive future indicator amid all this Pestell mishegas which seems to have come out of nowhere and should go right back there, remember that the description of CYDY in that market-analysis piece dfwl posted, which mentioned us first in the CCR-5 space, was NOT "Cytodyn, a company that has experienced turmoil and disaster and whose former CEO is on trial" etc etc, but rather:

"...in February 2024, CytoDyn Inc., a US-based biotechnology firm, announced that the U.S. Food and Drug Administration (FDA) had lifted the clinical hold on leronlimab, a CCR5 antagonist also known as PRO 140. This approval allows CytoDyn to proceed with its planned clinical trial to evaluate leronlimab's effects on chronic inflammation. Leronlimab shows potential for treating various health conditions, including HIV and cancer, due to its ability to target multiple diseases."

To me this is big, and something I keep coming back to, as fringe as it is: the tide is turning on the public narrative such that we're recognized as a serious company with the past *behind* us. We don't need to be dragged down by past associations. The future is so bright--I mean, mentioning LL in reference to inflammation, HIV and cancer and multiple diseases?? How much better can it get?!--and the investment community is seeing it too.